Celea Therapeutics Secures $180M Financing
Analysis based on 6 articles · First reported Jul 02, 2026 · Last updated Jul 02, 2026
The successful financing round for Bicara Therapeutics is expected to positively impact the biotechnology and pharmaceutical sectors, particularly companies focused on rare diseases. The advancement of deupirfenidone to a Phase 3 trial could create a new standard of care for idiopathic pulmonary fibrosis, potentially affecting the market for existing treatments and offering new investment opportunities in the respiratory disease space. Investors in Bicara Therapeutics, such as RA Capital Management, Bayer, and PureTech Health, are likely to see increased value in their holdings if the trial proves successful.
Bicara Therapeutics, a clinical-stage biopharmaceutical company, announced the completion of a $180 million financing round. The funding, with participation from RA Capital Management, Bayer, and founder PureTech Health, will support the planned early Q3 2026 initiation of the Phase 3 SURPASS-IPF trial for deupirfenidone (LYT-100). Deupirfenidone is an investigational next-generation antifibrotic intended to treat idiopathic pulmonary fibrosis (IPF), a rare and fatal lung disease. The trial will be a global, randomized, double-blind, head-to-head study comparing deupirfenidone against pirfenidone, one of the currently approved therapies for IPF. Deupirfenidone has received Orphan Drug Designation from both the United States — Food and Drug Administration and the International — European Commission. Previous Phase 2b trial results showed deupirfenidone's potential to stabilize lung function decline with a favorable safety profile.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard